AstraZeneca (AZN) withdraws listing for 1.200% Notes due 2026 from NYSE

Rhea-AI Filing Summary

AstraZeneca PLC has voluntarily withdrawn the listing/registration of its 1.200% Notes due 2026 from the New York Stock Exchange via Form 25, with the Exchange certifying compliance with the applicable withdrawal rules.

Key Figures

Coupon: 1.200% Maturity: due 2026 Commission File Number: 001-11960 +2 more

5 metrics

Coupon 1.200% Notes coupon

Maturity due 2026 Notes maturity year

Commission File Number 001-11960 SEC file identifier

Form type Form 25 Notification of removal from listing/registration

Document expiration March 31, 2018 printed expiration date on form

Key Terms

Form 25, Section 12(b), withdrawal of registration

3 terms

Form 25 regulatory

"FORM 25 NOTIFICATION OF REMOVAL FROM LISTING"

A Form 25 is an official filing with the U.S. Securities and Exchange Commission used to remove a company's stock or other security from a national exchange list. Investors should care because delisting often means less visibility, lower trading volume and wider price swings—similar to a product moving from a major supermarket to a small local market, which can make buying, selling and valuing the security more difficult.

Section 12(b) regulatory

"UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT"

Section 12(b) of the U.S. Securities Exchange Act requires securities listed on a national stock exchange to be registered with the U.S. Securities and Exchange Commission (SEC) and to follow regular public reporting and disclosure rules. For investors, a 12(b) listing generally means more routine financial updates, regulatory oversight and easier buying and selling—like a storefront that must display its inventory and prices, making it simpler to inspect and trade the product.

withdrawal of registration regulatory

"voluntary withdrawal of the class of securities from listing and registration"

UNITED STATES

OMB APPROVAL

OMB Number:			3235-0080
Expires:	March 31, 2018
Estimated average burden
hours per response:			1.7

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 25

NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION
UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934.

Commission File Number

001-11960

Issuer:	ASTRAZENECA PLC
Exchange:	NEW YORK STOCK EXCHANGE LLC

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered)

Address:	1209 Orange Street
	Wilmington	DELAWARE	19801
Telephone number:

(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)

Guarantor of 1.200% Notes due 2026

(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

17 CFR 240.12d2-2(a)(1)

17 CFR 240.12d2-2(a)(2)

17 CFR 240.12d2-2(a)(3)

17 CFR 240.12d2-2(a)(4)

Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange. ¹

Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with its rules of the Exchange and the requirements of 17 CFR 240.12d-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

Pursuant to the requirements fo the Securities Exchange Act of 1934, NEW YORK STOCK EXCHANGE LLC certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

2026-05-28	By	Tyler Mastronardi		Analyst, Market Watch
Date		Name		Title

¹ Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did AstraZeneca PLC (AZN) file with the SEC?

AstraZeneca filed a Form 25 notifying the SEC that the 1.200% Notes due 2026 will be withdrawn from listing on the New York Stock Exchange. The Exchange certified compliance with the withdrawal rules under Section 12(b) of the Exchange Act.

Does the Form 25 filing affect trading of AZN's other securities?

The filing pertains specifically to the 1.200% Notes due 2026. It does not state any change to AstraZeneca's other listed securities. The action is limited to the class of securities identified in the Form 25.

Who certified the removal of the AZN notes from NYSE listing?

The New York Stock Exchange LLC certified the Form 25 and stated it complied with the applicable withdrawal rules. The notification is signed by an Exchange official identifying compliance with 17 CFR 240.12d2-2 procedures.

What is the security being removed for AZN and its principal terms?

The filing identifies the security as the issuer/guarantor of the 1.200% Notes due 2026. The document lists the Commission File Number 001-11960 and references the Exchange withdrawal procedures under Section 12(b).